期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Drug-induced gingival overgrowth in cardiovascular patients 被引量:1
1
作者 Lucija Bajkovec Anna Mrzljak +1 位作者 Robert Likic Ivan Alajbeg 《World Journal of Cardiology》 2021年第4期68-75,共8页
Drug-induced gingival overgrowth(DIGO)is a pathological growth of gingival tissue,primarily associated with calcium channel blockers and immunosuppressants.Consequently,it is mainly seen in cardiovascular and transpla... Drug-induced gingival overgrowth(DIGO)is a pathological growth of gingival tissue,primarily associated with calcium channel blockers and immunosuppressants.Consequently,it is mainly seen in cardiovascular and transplanted patients.Nifedipine remains the main calcium channel blocker related to the development of this unpleasant side-effect.As for immunosuppress-ants,cyclosporin is the leading causative agent,whereas other drugs from this druggroup,including tacrolimus,have better safety profiles.Accumulated collagen with inflammatory infiltrates is the histological hallmark of this condition.Several factors are involved in the pathogenesis and can increase the risk,such as male gender,younger age,pre-existing periodontal inflammation,and concomitant use of other DIGO-inducing medications.Patients with DIGO may experience severe discomfort,trouble with speech and mastication,pain,and teeth loss,aside from cosmetic implications.Furthermore,these patients also have an increased risk for cardiovascular diseases.The interdisciplinary approach and cooperation with dental care experts are necessary for patient management.Treatment includes discontinuing the drug and switching to one with a better profile,improving oral hygiene,and surgical removal of enlarged tissue.Recognizing the potential of commonly used medications to cause DIGO and its effect on patients'health is necessary for early detection and adequate management of this complication. 展开更多
关键词 drug-induced gingival overgrowth Calcium channel blocker NIFEDIPINE
下载PDF
钙离子拮抗剂致老年人牙龈增生危险因素分析 被引量:1
2
作者 毛静 米婷 +2 位作者 王艳丽 郝锦霞 冯洁 《中华老年口腔医学杂志》 2021年第2期97-100,104,共5页
目的:数据分析西安交通大学医院内科门诊的高血压或其他心血管疾病患者服用的钙离子拮抗剂对诱导牙龈增生的影响。方法:经筛选后符合此次调研标准的2019年我院内科门诊的高血压或其他心血管疾病的临床资料共483份,其中服用钙离子拮抗剂(... 目的:数据分析西安交通大学医院内科门诊的高血压或其他心血管疾病患者服用的钙离子拮抗剂对诱导牙龈增生的影响。方法:经筛选后符合此次调研标准的2019年我院内科门诊的高血压或其他心血管疾病的临床资料共483份,其中服用钙离子拮抗剂(Calcium Channel Blockers,CCB)者252例,未服用CCB(对照组)186例。记录调查人员的性别、年龄、用药时间及习惯,并进行口腔检查。结果:通过对调查数据进行分析,服用CCB者,患有药物性牙龈增生比率为33.33%,未服用CCB(对照组)186例,患有药物性牙龈增生比率5.38%,CCB组显著高于对照组的患病比率;用药时间与用药方式对诱导牙龈增生有着一定的影响,其中用药时间在6个月到1年之间及1年-2年的时间段患病率最高。结论:此次调查识别出钙离子拮抗剂引起药物性牙龈增生的影响因素,对于以后钙离子拮抗剂在心血管疾病中的使用,以及在改善口腔卫生和牙龈健康方面都有着重要的作用。 展开更多
关键词 钙离子拮抗剂 药物性牙龈增生 患病率
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部